Insight From Drs. Loretta Nastoupil and Michael Pulsipher


We report on the ASH annual meeting of 2021!

We highlight some of the key news presented each day at the meeting – and soon we’ll be featuring Dr. Loretta Nastoupil speaking about some exciting non-Hodgkin lymphoma studies, Dr. Jacqueline Barrientos on the latest advances in chronic lymphocytic leukemia, Dr. Michael Pulsipher on intriguing childhood cancer research.

Welcome to the OncLive news network! I’m Gina Mauro.

Updated results from the phase 2 GRIFFIN trial showed that the combination of daratumumab, lenalidomide, bortezomib, and dexamethasone continued to demonstrate profound and durable responses, including strict complete response and minimal residual disease egativity, in eligible patients with newly diagnosed multiple myeloma for transplant.

In the phase 2 HOVON 143 study, intermediate-fit patients with multiple myeloma were shown to benefit from ixazomib, daratumumab, and dexamethasone. However, discontinuation of therapy due to toxicity remains a concern with this combination.

In light chain amyloidosis, an 18-month analysis of the phase 3 ANDROMEDA study showed that subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone demonstrates sustained clinical benefits over VCd alone in terms of hematologic and organ responses with longer follow-up . However, many patients in the D-VCd arm received daratumumab monotherapy as monotherapy after 6 cycles of D-VCd, and patients in the VCd arm discontinued study treatment.

MRD-guided, time-limited treatment with ibrutinib and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia who have undetectable MRD is feasible and shows a favorable benefit-risk profile, according to a primary analysis of the Phase 2 VISION HO141- study.

Also in CLL, the all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD responses that were deeper and more sustained after treatment versus chlorambucil/obinutuzumab in elderly or unfit patients with previously untreated disease, as seen in the phase 3 GLOW study.

Be sure to check out more of our coverage of the 2021 ASH Annual Meeting on

That’s all for today. Tomorrow we will sit down virtually with Dr. Nina Shah, who will unpack the crucial results of multiple myeloma.

Thanks for watching OncLive News Network: On Location, I’m Gina Mauro.

Comments are closed.